Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-04-13 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司关于2022年年度股东大会股权登记日的公告
AGM Information Classification · 95% confidence The document is an announcement regarding the record date for shareholders to be eligible to attend and vote at the 2022 Annual General Meeting (AGM) of BeiGene Ltd. It specifies the share registration dates for different classes of shareholders and mentions that further details about the AGM will be disclosed later. The document does not contain the AGM materials or minutes themselves, nor does it include financial statements or voting results. It is a notice related to the AGM process, specifically about the share registration date, which is a typical content of AGM Information announcements. The document length is short (1551 characters), and it is clearly an announcement rather than the full AGM report or materials. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-04-13 Chinese
百济神州有限公司自愿披露关于百悦泽（泽布替尼胶囊）临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding clinical trial progress of their drug BeiYueZe (Zebutinib capsules). It provides detailed clinical trial results, safety data, and risk warnings related to the drug's development and regulatory approval prospects. The document is relatively short (2137 characters) and is an announcement of clinical trial progress rather than a financial report or regulatory filing. It does not contain financial statements, earnings data, or governance information. It is not a report publication announcement since it contains substantive clinical trial data and risk disclosures. The content fits best under a Regulatory Filings (RNS) category as it is a regulatory disclosure about clinical trial progress and associated risks, which does not fit other more specific categories.
2022-04-11 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司 (BeiGene, Ltd.) as required under the Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A / GEM Rule 17.27A). It details share issuance under an employee share scheme, share counts before and after issuance, and compliance confirmations. The document is short (2880 characters) and is a regulatory disclosure of share capital changes rather than a full financial report or announcement of a report. It fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital changes. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2022-04-08 Chinese
港股公告：证券变动月报表
Share Issue/Capital Change Classification · 95% confidence The document is a monthly securities movement report for a listed issuer and its Hong Kong Depositary Receipt issuer under Chapter 19B of the Listing Rules. It details changes in registered capital, issued shares, share options, and confirmations related to share issuance and compliance with listing requirements. The document is structured as a regulatory monthly report on share capital and securities movements, not a financial report, earnings release, or management discussion. It is not an announcement of voting results, board changes, or legal proceedings. The content fits the category of Share Issue/Capital Change announcements, as it reports on share issuance, share option exercises, and related capital changes for the month ending March 31, 2022. The document length is about 4794 characters, which is substantive and contains detailed data on share capital changes, not just a brief announcement or certification. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-04-07 Chinese
百济神州有限公司自愿披露关于百泽安（替雷利珠单抗注射液）新适应症上市许可申请获得欧洲药品管理局受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding the acceptance by the European Medicines Agency (EMA) of a new indication marketing authorization application for their drug 百泽安 (Tislelizumab Injection). It details the drug, clinical trials, and risk factors related to the approval process. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement of a regulatory event related to drug approval, not a financial report or management report. It is also not a certification or voting result. Given the nature and length (2234 characters), it is a regulatory announcement about a material event affecting the company. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-04-06 Chinese
港股公告：授出购股权
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from BeiGene, Ltd. regarding the granting of stock options under the 2016 Option and Incentive Plan. It details the number of options granted, exercise price, vesting schedule, and other terms. The document is not a financial report, earnings release, or management discussion. It is not a regulatory certification or a report publication announcement. The content focuses on the granting of share options to employees, which is a capital-related event but specifically about stock options granted, not a new share issue or capital change announcement like stock splits or new share issuance. This type of announcement fits best under the category of Director's Dealing or Transaction in Own Shares if it involved directors or company buying/selling shares, but here it is about granting options to employees, which is a capital/financing update related to equity compensation plans. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (2297 characters), consistent with an announcement rather than a full report.
2022-04-05 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.